industry
Life sciences risk financing: clinical trials, products and long-tail liability
A company running clinical trials and one selling approved products face different liabilities, and many do both. Separate them early, because they develop differently and are supported by different evidence.
Clinical, product and long-tail risks in life sciences and pharmaceuticals, with specialists who work in the sector.
0 active providers
How are these providers ranked?Common risks and risk-financing considerations in Life Sciences & Pharmaceuticals
- Clinical development versus commercial products — Trial liability depends on protocols, sites and sponsor agreements; marketed-product liability depends on distribution and use. Keep them as separate exposures.
- Product liability, recall and contracts — FDA-regulated products can be recalled, and supply, manufacturing and licensing agreements often allocate liability between partners. Read those agreements to see what the company retains.
- Long-tail uncertainty and data quality — Claims can emerge long after exposure, and a short loss history may not show the real risk. Ask how specialists would evaluate a retained layer with limited data.
- Questions for specialists — Ask which product types and development stages a provider has worked with, and who handles regulatory and contract questions. A single-parent captive can be discussed, but only once the retained exposure is clear.
Providers serving Life Sciences & Pharmaceuticals
Each card shows why that provider is relevant to Life Sciences & Pharmaceuticals, from what the provider has recorded against this industry.